Logo

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Share this

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Shots:

  • The first patient has been dosed in a P-II cancer vaccine trial evaluating the efficacy- tolerability & safety of BNT111 + Libtayo in combination or as monothx in 120 patients with anti-PD1 r/r unresectable Stage III or IV melanoma in EU. The company also plans to start P-II trial in 2 additional programs with BNT111 in 2021
  • The 1EPs of a trial is ORR & 2EP includes ORR in monothx arms- DoR- & safety. The company holds global commercial rights to BNT111
  • The P-II trial is based on previous results from a P-I Lipo-MERIT dose-escalation trial that demonstrates a favorable safety profile for BNT111 & DOR was observed in patients with melanoma who had progressed following prior checkpoint blockade

  | Ref: Globe Newswire | Image: Hindustan Times

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions